Ethris
Ethris is using its proprietary messenger RNA technology platform to enable the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues.
The German biotech is focused internally on a strategic set of respiratory disorders, and works with partners to realize the potential for its patented SNIM RNA transcript therapies in various areas of human disease.
In 2017, Ethris announced a five-year strategic research collaboration with AstraZeneca focused on developing new stabilized non-immunogenic modified RNA therapies for respiratory diseases using SNIM RNA technology.
Latest Ethris News & Features
30 December 2022
4 June 2019
21 August 2017
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze